Opendata, web and dolomites

RETHRIM SIGNED

Restoring tissue regeneration in patients with visceral Graft versus Host Disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RETHRIM project word cloud

Explore the words cloud of the RETHRIM project. It provides you a very rough idea of what is the project "RETHRIM" about.

potency    collect    conduct    academic    stromal    clinical    safety    outcome    body    expertise    bone    treatment    published    first    indirect    infrastructure    stem    cells    quality    variety    stone    prediction    regeneration    form    serve    resistant    recruited    mechanisms    central    efficacy    latter    signature    acute    data    beginning    stepping    graft    markers    msc    tissue    anti    visceral    commercialization    trial    150    organ    mesenchymal    disorders    cartilage    harmonized    host    intend    positive    capacity    ethical    designation    injury    relies    repair    steroid    molecular    health    functional    randomized    versus    progenitor    extensively    rethrim    orphan    life    hold    disease    combined    cell    regenerative    placebo    endogenous    tissues    date    undergoing    therapeutic    mechanism    additional    analysed    patients    promise    hampering    shown    direct    drug    therapies    once    inflammatory    thereby    suffering    gvhd    therapy   

Project "RETHRIM" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.rethrim.eu
 Total cost 5˙857˙587 €
 EC max contribution 5˙857˙587 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-single-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 2˙334˙931.00
2    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 660˙043.00
3    IMMUNOTOOLS GMBH DE (Friesoythe) participant 534˙025.00
4    FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON ES (SORIA) participant 399˙787.00
5    GenomeScan B.V. NL (Leiden) participant 370˙000.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 354˙850.00
7    LUNDS UNIVERSITET SE (LUND) participant 333˙200.00
8    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 331˙537.00
9    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) participant 309˙300.00
10    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 229˙912.00
11    GENOMIC INVESTMENTS BV NL (LEIDEN) participant 0.00
12    STICHTING HEMATO-ONCOLOGIE VOOR VOLWASSENEN NEDERLAND (HOVON) NL (Amsterdam) participant 0.00

Map

 Project objective

Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body.

Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions aiming at repair through direct or indirect mechanisms. Their ability to form bone or cartilage is used to directly repair these tissues. In other conditions their regenerative effects are based on endogenous repair through their anti-inflammatory properties. The latter mechanism is important in the treatment of acute Graft-versus-Host Disease (GvHD). We have been involved in the clinical development from the beginning and we have shown the therapeutic potential. However, no results of controlled randomized phase 3 studies have been published to date, thereby hampering safety and efficacy assessment.

Within our consortium we have developed an academic infrastructure for the harmonized production of MSC. In the RETHRIM proposal this will be combined with our clinical expertise to conduct the first Europe-wide placebo controlled randomized phase III trial using MSC regenerative therapy for the treatment of steroid-resistant visceral GvHD. Central to the RETHRIM project is the clinical trial for which 150 patients will be recruited. All MSC products will be extensively analysed using molecular and functional markers, in order to develop a potency signature for the product and for the prediction of response. We also intend to collect data from additional quality of life, health technology assessment and ethical studies. We will apply for an Orphan Drug Designation in Europe and this may serve as a stepping-stone for the further commercialization of the MSC product, once a positive outcome has been obtained.

 Deliverables

List of deliverables.
Website Websites, patent fillings, videos etc. 2020-02-12 08:28:27

Take a look to the deliverables list in detail:  detailed list of RETHRIM deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Frederick W. Thielen, Hedwig M. Blommestein, Liesbeth E.M. Oosten, Friso G. Calkoen, Arjan C. Lankester, Jaap J. Zwaginga, Katarina Le Blanc, Alba Redondo, Fermin Sánchez-Guijo, Mattia Algeri, Franco Locatelli, Wim E. Fibbe, Carin A. Uyl-de Groot
Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model
published pages: 676-683, ISSN: 0902-4441, DOI: 10.1111/ejh.13158
European Journal of Haematology 101/5 2020-02-12
2016 Koen Schepers, Willem E. Fibbe
Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization
published pages: 15-23, ISSN: 0077-8923, DOI: 10.1111/nyas.12984
Annals of the New York Academy of Sciences 1370/1 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETHRIM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETHRIM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More